Revelation Biosciences Inc. Warrant (REVBW)
REVBW trades on Nasdaq in Health Care, Biotechnology: Pharmaceutical Preparations. Numbers below come from the Nasdaq screener and SEC filings, each with its source.
Price · October 14, 2026
$0.0051
-33.77% on the day
Market cap
$20K
Nano cap
Revenue
Warrant: not a share of the company
Net income
Warrant: not a share of the company
Price, change, market cap, sector and industry: Nasdaq stock screener, as of October 14, 2026.
Profile
| Field | Value |
|---|---|
| Ticker | REVBW on Nasdaq |
| Sector | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations |
| Country | United States |
| IPO year | 2020 |
| SEC CIK | 0001810560 |
| SEC industry code | Pharmaceutical Preparations |
| Incorporated in | DE |
Financials
Warrant: not a share of the company.
Key SEC documents
| Document | Form | Filed |
|---|---|---|
| Latest prospectus or offering document | 424B3 | 2026-02-11 |
| Latest annual report | 10-K | 2026-02-26 |
| Latest quarterly / interim | 10-Q | 2026-08-06 |
| Latest current report | 8-K | 2026-08-19 |
| Latest proxy | DEF 14A | 2026-05-11 |
Source: SEC EDGAR submissions feed, 387 recent filings. All filings on EDGAR.
Other listings for this company
| Ticker | Name | Price |
|---|---|---|
| REVB | Revelation Biosciences Inc. | $0.7302 |
Peers in Biotechnology: Pharmaceutical Preparations
| Ticker | Company | Price | Day | Market cap |
|---|---|---|---|---|
| ERNAW | Ernexa Therapeutics Inc. Warrants | $0.0280 | -6.67% | $46K |
| CDT | CDT Equity Inc. | $0.4500 | -31.82% | $506K |
| SXTC | China SXT Pharmaceuticals Inc. | $0.0774 | -24.12% | $802K |
| BDRX | Biodexa Pharmaceuticals plc American Depositary Shs | $0.3502 | -8.61% | $1.5M |
| ARTL | Artelo Biosciences Inc. | $2.98 | -4.18% | $1.6M |
| LABT | Lakewood-Amedex Biotherapeutics Inc. | $0.6939 | -5.08% | $1.6M |
| OGEN | Oragenics Inc. | $0.4469 | -0.16% | $2.0M |
| GNPX | Genprex Inc. | $2.51 | -6.69% | $2.1M |
The full dossier has every filing, three years of financials, private raises and the people who signed them.
Open the full dossier